Abstract
Cytotoxic T cells are the most powerful immune arsenals against cancers. Exploiting this potential has been difficult when using conventional αβ T cells primed to recognize specific tumor-associated peptides. Fortunately, vertebrates come equipped with such anti-tumor cytotoxic T cells that bear the γδ T-cell receptor and intrinsically recognize malignancy-associated antigens. Nitrogen-bisphosphonates (n-BP) are the main class of drugs currently used to manage cancer-associated bone disease. Unexpectedly, n-BP have the specific side-effect of potently activating the anti-tumor effector functions of human peripheral blood γδ T cells. Given the rarity of such therapeutic synergism, little time has been wasted to determine how to best harness the anti-cancer abilities of γδ T cells and n-BP for the treatment and prevention of cancer metastasis. In this chapter we provide an overview of the major breakthroughs of this unique immunotherapeutic strategy which may be the most promising immune approach yet for bone cancer metastasis.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
